Avon and Wiltshire Mental Health Partnership NHS Trust Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2014
NCT01843075
First Marketed Drug
2007
lisdexamfetamine (vyvanse)
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

SHIRE DEVELOPMENT

Active Ingredients

Marketed Drugs (1)

lisdexamfetamine (vyvanse) (2007)

Drugs in Phase 2 Trials (1)

liraglutide (victoza) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1